Role nemocničního farmaceuta v managementu astmatu ve Velké Británii

English version

Autoři: Inka Sembol; Božena Macešková
Vyšlo v časopise: Čes. slov. Farm., 2017; 66, 112-116
Kategorie: Původní práce

Souhrn

Role farmaceuta v managementu astmatu je opodstatněná. Avšak stále je podstatný počet pacientů se suboptimální kontrolou astmatu, což ovlivňuje kvalitu jejich života a vede k nedostatečným výsledkům, morbiditě a mortalitě. Cílem bylo identifikovat faktory na straně pacienta, zhodnotit roli nemocničního lékárníka v managementu astmatu ve Velké Británii a identifikovat oblasti, kde by mělo dojít ke zkvalitnění. Byla zvolena metoda sběru dat kvalitativní povahy. Byly provedeny case studies s pacienty, semistrukturované, otevřené pohovory s pracovníky multidisciplinárního nemocničního týmu (MDT). Data byla analyzována a seskupena podle témat. Pacientské studie ukázaly variabilitu v porozumění roli farmaceuta v managementu jejich astmatu, a podobnost v chápání jim dostupných služeb nabízených lékárnou. Z rozhovorů s členy MDT vyplynulo, že komunikace mezi sekundární a primární péčí má nedostatky. Je tedy zřejmé, že zde je prostor pro zkvalitnění, zvláště v implementaci komunikačních systémů. Další výzkum je potřebný v oblasti potřeb pacientů- astmatiků a očekávání kladených na služby poskytované lékárnou. Nemocniční lékárníci jsou v dobré pozici identifikovat astmatické pacienty vyžadující farmaceutickou intervenci, provedení optimalizace farmakoterapie napříč primární a sekundární péčí. Bylo zjištěno, že úroveň pacientova přístupu ke svému astmatu je závislá na jeho zájmu a na využívání informací a služeb poskytovaných lékárnou.

Klíčová slova:
astma • management astmatu • nemocniční lékárník • sekundární péče • case studies • kvalitativní výzkum

Zdroje

1. Levy S. K., et al. Why asthma still kills: the National Review of Asthma Deaths. Confidential Enquiry report. London: Royal College of Physicians 2014.

2. APPG. APPG on respiratory health: Report on Enquiry into Respiratory Deaths. 2014. https://www.asthma.org.uk/globalassets/campaigns/appg_respiratory_deaths_2014_online.pdf

3. Partridge M. R., van der Molen T., Myrseth S. E., Busse W. W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmonary Medicine 2006; 6, 13.

4. Price D., Fletcher M., van der Molen T. Asthma control and management in 8000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. Primary Care Respiratory Medicine 2014; 24, 14009.

5. Rabe K. F., Vermeire P. A., Soriano J. B., Maier W. C. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. The European Respiratory Journal 2000; 16: 802–807.

6. Demoly P., Annunziata K., Gubba E., Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. European Respiratory Review 2012; 21: 66–74.

7. GLOBAL ASTHMA NETWORK: The global asthma report. Auckland, New Zealand: 2014.

8. European Respiratory Society – European Lung White Book 2013. http://www.erswhitebook.org/chapters/adult-asthma/

9. ASTHMA UK: Health Advice. 2016. https://www.asthma.org.uk/advice/

10. Walker R., Whittlesea C. Clinical Pharmacy and Therapeutics. 5th ed. London: Churchill Livingstone Elsevier 2012; 998 p.

11. BRITISH THORACIC SOCIETY and SCOTTISH INTERCOLLEGIATE GUIDELINES NETWORK (BTS&SIGN): The British guideline on the management of asthma. A national clinical guideline SIGN 141.2014. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2014/

12. Katzung B. G., Masters S. B., Trevor A. J. Basic and Clinical Pharmacology, 14th ed. McGraw Hill, Lange 2016; 1310 p.

13. Khachi H., Meynell H., Murphy A. Asthma: Long-term management. Clinical Pharmacist. 2014; 9, 225–228.

14. D’Ancone G. Inhaled corticosteroids: managing side effects. The Pharmaceutical Journal 2015; 294(7851), 247–249.

15. Kerstjens H. A. M., et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallelgroup, active-comparator, randomised trials. Lancet 2015; 3(5), 367–376.

16. Murphy A. Asthma: treatment and monitoring. Clinical Pharmacist 2010; 2, 209–214.

17. Papi A., et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet 2013; 1(1), 23–31.

18. Patel M., et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet 2013; 1(1), 32–42.

19. Thomson N. Recent advances in the treatment and management of asthma. The Prescriber 2015; 19, 17–24.

20. NICE: Quality standards for asthma. 2013. http://www.nice.org.uk/guidance/qs25

21. Dominguez-Ortega J., et al. Cost-effectiveness of asthma therapy: A Comprehensive review. Journal of Asthma 2014; 52(6), 1–23.

22. DiCicco-Bloom B., Crabtree B. F. The qualitative research interview. Medical Education 2002; 40(4), 314–321.

23. Babar Z. Pharmacy Practice Research Methods. London: Springer International Publishing AG 2015; 251 p.

24. Fathima M., et al. The role of community pharmacists in screening and subsequent management of chronic respiratory diseases: a systematic review. Pharmacy practice 2013; 11(4), 228–245.

25. Adunlin G., et al. The Effectiveness of Pharmacist Interventions on Asthma Management: a systematic review. Journal of asthma and allergy educators 2012; 3(6), 264–273.

26. Peytremann- Bridevaux I., et al. Chronic disease management programmes for adults with asthma. Cochrane Database of Systematic Reviews. 2015. Issue 5.

27. RPS Clinical Governance. 2016. http://www.rpharms.com/support-resources-a-z/clinical-governance-quick-reference-guide.asp

28. BRITISH LUNG FOUNDATION Asthma 2016. https://www.blf.org.uk/support-for-you/asthma

29. GPhC Standards of conduct, ethics and performance 2012. https://www.pharmacyregulation.org/sites/default/files/standards_of_conduct_ethics_and_performance_july_2014.pdf

30. NICE: Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes 2015. https://www.nice.org.uk/guidance/ng5

31. NICE: Patient experience in adult NHS services: improving the experience of care for people using adult NHS services. Clinical Guideline 138, 2012. https://www.nice.org.uk/guidance/cg138

32. NHS England: Confidentiality Policy 2014. https://www.england.nhs.uk/wp-content/uploads/2013/06/conf-policy-1.pdf

33. Department of Health: Equity and excellence: Liberating the NHS 2010. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_117794.pdf

34. GENERAL MEDICAL COUNCIL: The Good Medical Practice. 2014. http://www.gmc-uk.org/guidance/good_medical_practice.asp

35. NHS England. Confidentiality: The NHS Code of Practice 2003. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/200146/Confidentiality_-_NHS_Code_of_Practice.pdf

36. JuniperE. F., et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. The European Respiratory Journal 1999; 14(1), 32–38.

37. Millard M., Hart M., Barnes S. Validation of Rules of Two ™ as a paradigm for assessing asthma control. Proceedings (Baylor University Medical Centre) 2014; 27(2), 79–82.

38. Gurkova E., Popelkova P. Validity of Asthma Control Test in Assessing Asthma Control in Czech Outpatient Setting. Central European Journal of Public Health 2015; 23(4), 286–291.

39. Naik-Panvelkar P., et al. A pharmacy asthma service achieves a change in patient responses from increased awareness to taking responsibility for their asthma. The International journal of pharmacy practice 2015; 23(3), 182–191.

40. Pinnock H., et al. Systematic meta-review of supported self-management for asthma: a healthcare perspective. BMC Medicine 2017; 15(64), 1–32.

41. Lingner H., et al. What patients really think about asthma guidelines: barriers to guideline implementation from the patients’ perspective. BMC Pulmonary Medicine 2017; 17(13), 1–12.

42. Peláez S., et al. Patients’ perspective of barriers and facilitators to taking long-term controller medication for asthma: a novel taxonomy. BMC Pulmonary Medicine 2015; 15(42), 1–11.

43. Macešková B., Fridrichová D. Monitorování terapie astmatických pacientů v lékárně. Klinická farmakologie a farmacie 2005; 19: 206–210.